Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuma Kishida

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
International Journal of Clinical Oncology|April 10, 2025
Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancerRyutaro Onaga, Tomohiro Enokida, Shingo Sakashita, et al.
International Journal of Clinical Oncology|July 23, 2024
Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancerRyutaro Onaga, Tomohiro Enokida, Susumu Okano, et al.
Oral Oncology|May 8, 2025
Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapyRyutaro Onaga, Tomohiro Enokida, Hirofumi Kuno, et al.
Head & Neck|April 3, 2026
Significance of Preoperative Imaging-Detected Extranodal Extension in Pathological Extranodal Extension-Positive Head and Neck Squamous Cell Carcinoma Treated With Postoperative ChemoradiotherapyYuta Hoshi, Hirofumi Kuno, Shingo Sakashita, et al.
Oral Oncology|March 9, 2025
Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE)Nobukazu Tanaka, Tomohiro Enokida, Susumu Okano, et al.
Frontiers in Oncology|June 7, 2024
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastomaYuta Hoshi, Tomohiro Enokida, Shingo Tamura, et al.
Anticancer Research|May 29, 2023
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective StudyTakuro Okada, Chihiro Fushimi, Takashi Matsuki, et al.
Anticancer Research|February 27, 2026
Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS StatusYuri Ueda, Takuro Okada, Isaku Okamoto, et al.
Anticancer Research|August 28, 2024
Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With PembrolizumabKohei Hagiwara, Takashi Matsuki, Takuro Okada, et al.
Current Oncology (Toronto, Ont.)|January 27, 2026
Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 TrialGai Yamashita, Takuro Okada, Isaku Okamoto, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Clinical Oncology|April 10, 2025
Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancerRyutaro Onaga, Tomohiro Enokida, Shingo Sakashita, et al.
International Journal of Clinical Oncology|July 23, 2024
Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancerRyutaro Onaga, Tomohiro Enokida, Susumu Okano, et al.
Oral Oncology|May 8, 2025
Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapyRyutaro Onaga, Tomohiro Enokida, Hirofumi Kuno, et al.
Head & Neck|April 3, 2026
Significance of Preoperative Imaging-Detected Extranodal Extension in Pathological Extranodal Extension-Positive Head and Neck Squamous Cell Carcinoma Treated With Postoperative ChemoradiotherapyYuta Hoshi, Hirofumi Kuno, Shingo Sakashita, et al.
Oral Oncology|March 9, 2025
Induction chemotherapy and concurrent chemoradiotherapy with cisplatin for T4 nasoethmoidal squamous cell carcinoma: The value of paclitaxel, carboplatin and cetuximab (PCE)Nobukazu Tanaka, Tomohiro Enokida, Susumu Okano, et al.
Frontiers in Oncology|June 7, 2024
Efficacy of anti-PD-1 monotherapy for recurrent or metastatic olfactory neuroblastomaYuta Hoshi, Tomohiro Enokida, Shingo Tamura, et al.
Anticancer Research|May 29, 2023
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective StudyTakuro Okada, Chihiro Fushimi, Takashi Matsuki, et al.
Anticancer Research|February 27, 2026
Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS StatusYuri Ueda, Takuro Okada, Isaku Okamoto, et al.
Anticancer Research|August 28, 2024
Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With PembrolizumabKohei Hagiwara, Takashi Matsuki, Takuro Okada, et al.
Current Oncology (Toronto, Ont.)|January 27, 2026
Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 TrialGai Yamashita, Takuro Okada, Isaku Okamoto, et al.
Pageof 3